Summary Studies using monoclonal antibody MR6, which is thought to bind to the interleukin-4 growth factor receptor (IL-4R), indicate that IL-4R molecules are upregulated in tumours of epithelial origin and that radiolabelled MR6 is effective as an in vivo tumour imaging agent. Immunohistochemical analysis of a wide range of solid tumours using monoclonal antibody MR6 has demonstrated elevated expression of the IL-4R on a variety of carcinomas. The equivalent normal tissue showed either weak or no expression of this molecule. No other tumours studied were positive. The molecular weight of the receptor on tumour cells was indistinguishable from that on normal tissue. These data raise the possibility that the IL-4R is the product of a novel oncogene such that elevated expression of this growth factor receptor could be involved in the process of carcinogenesis. Monoclonal antibodies to the IL-4R, such as MR6, may therefore be useful reagents not only for diagnosis and immunoscintigraphy, but also for in vivo antibody-guided therapy of epithelial cancers.
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Monoclonal antibodies to tumour-associated antigens are becoming increasingly important in clinical oncology. For tumour imaging, small doses of radiolabelled antibody can be used in vivo to localise the tumour by gamma-camera imaging (Mach et al., 1981; Farands et al., 1982; Epenetos et al., 1985b) . For therapy, larger in vivo doses of antibody are used to target a lethal substance such as a radionuclide or toxin to the site of the tumour (Larson et al., 1983; Miller et al., 1983; Epenetos et al., 1984; Spitler et al., 1987) . Although few antigens are truly tumour specific, molecules such as growth factors have proved to be useful target antigens on tumour cells (Epenetos et al., 1985a) .
Growth factors comprise a family of protein molecules that regulate cell proliferation and number, with each factor acting on a different range of cell types. Target specificity and cell activation are controlled by the specific cell surface receptors to which these soluble ligands bind. Excessive or inappropriate expression of the receptor for a growth factor can contribute to the multistage process of oncogenesis (Bishop, 1983; Land et al., 1983; Hudziac et al., 1987) . Thus, as in the case of the receptor for epidermal growth factor (EGF-R), a molecule that is expressed at low levels on normal cells is present at highly elevated levels on the equivalent tumour tissue (Ullrich et al., 1984; Merlino et al., 1984) .
Interleukin 4 (IL-4; formerly B cell growth factor, B cell stimulatory factor-1) is a pleiotropic T-lymphocyte derived factor that was first identified by its ability to enhance the proliferation of B lymphocytes that had been stimulated with anti-IgM antibodies (Howard et al., 1982) . More recently it has also been found to induce T-lymphocyte proliferation (Lee et al., 1986; Mosmann et al., 1986; Fernandez-Botran et al., 1986; Hu-Li et al., 1987) . Recombinant IL-4 has been used in cross-linking studies to show that the receptor for this lymphocyte growth factor/lymphokine has a molecular weight of approximately 139kD and is present at low levels on T and B lymphocytes, monocytes, promyelocytes, mast cells, fibroblasts and some epithelial cell lines (Park et al., 1987) .
We have recently described a monoclonal antibody that we believe binds to the human IL-4 receptor (Larche et al., 1988a, b (De Maagd et al., 1985) .
Western blotting Details of this method have been described previously (Larche et al.. 1988b) . Bnrefly. 108 thymocytes or I cm3 of normal thymus or ovarian carcinoma tissue were lysed in 0.50% NP40 containing pjug ml -aprotonin. The solubilised material was separated by 10% SDS-PAGE followed by electrophoretic transfer to a mntrocellulose membrane (BioRad. Watford. UK). Unoccupied charged sites on the membrane were blocked by overnight incubation at 4-C in PBS containing 2.5% skimmed milk powder (Marvel, Cadbury Schweppes Ltd. Birmingham). PBS containing 0.5% skimmed milk powder was used subsequently for all antibody dilutions and for washing the membranes. Strips of the membrane were incubated for 2 h with primary antibody (either MR6 or an isotype-matched negative control), washed. incubated with peroxidase-conjugated rabbit antimouse Ig antibody (Dakopatts) for 30 min and washed again. The peroxidase reaction was developed using 4-chloro-l-napthol followed by 3,3-diaminobenzidine.
Tumour imaging with MR6 MR6 was produced as bulk tissue culture supernatant, purfied by protein A affinity chromatography, tested for sterilitv and pyrogenicity and coupled to "'In using the cyclic anhydnrde of Diethylenetniaminepentaacetic acid (DTPA; Sigma, UK), as previously described (Hnatowich et al.. 1983) . One adult male patient with carcinoma of the lung was given an intravenous dose of 0.5mg MR6 labelW with Tumour imaging Immediately after administration of "'1In-labelled monoclonal antibody MR6 activity was present throughout the blood pool (Figure 4a ). However, this cleared to reveal significant uptake of MR6 into the tumour site at 48 h ( Figure 4b ).
Disassi
In this paper we show that the antigen detected bv the (Adamson, 1987) . In our survey of 20 epithelial tumours all were strongly IL-4R positive. However, to determine whether IL-4R expression is elevated on all carcinomas will require analysis of a much larger number of samples; these studies are in progress. It is well documented that other oncogene products such as the EGF receptor and c-erb-B protein are also elevated in epithelial tumours (Ullrich et al., 1984; Merlino et al., 1984; Berger et al., 1987; Cerny et al., 1986; Slamon et al., 1987) . For example, 80% of lung squa-mous celtpa show high EGFR expression while 20% of breast ca have amplified copies of the c-erb-B gene (Berger et al., 1987; Cerny et al., 1986; Slamon et al., 1987) . The relationship between these oncogene products and the IL-4R is unknown, although since oncogenesis is probably a multistage process, the presence of two or more such molecules may be required for autonomous growth of tumour cells.
Our observations concerning the elevation of IL-4R on carcinoma could be exploited in clinical medicine both in the diagnosis and detection of disease and in in vivo antibodyguided therapy. Recent data have shown that amplification of certain oncogenes and their products correlates with disease prognosis in breast, lung and bladder carcinoma (Slamon et al., 1987; Berger et al., 1987; Harris et al., 1988) .
Studies are therefore in-progress to determine whether the level of expression of MR6-Ag/IL-4R can also be used as an Figure 4 Gamma-camera scan (anterior) of patient with lung carcinoma given 0.5mg "'In-labelled (1.2mCi) MR6 monoclonal antibody, taken immediately (a) and after 48 h (b). In (a) the antibody is distributed throughout the blood pool. In (b) MR6 is localised within the tumour mass (arrow).
indicator of prognosis in neoplastic disease. In addition, once the gene for this molecule has been cloned (work in progress), gene amplification studies will also be performed.
Our preliminary immunoscintigraphic data suggest that monoclonal antibodies to the IL-4R, such as MR6, may prove to be useful tools for in vivo imaging of metastatic disease. More importantly, perhaps, these antibodies could be used as cytotoxic agents in in vivo immunotherapytargeting lethal radionuclides, toxins or drugs to the tumour site. Furthermore, such reagents with specificity for the IL-4R could have two important advantages when compared with many of the monoclonal antibodies in current use. Firstly, since MR6 has been shown to inhibit IL-4 induced T-lymphocyte proliferation in vitro (Larche et al., 1988a ) it might exert a comparable effect on IL-4R bearing epithelial cells in vivo and thus act as a direct cytostatic agent as well as performing its role as a 'magic bullet'. Secondly, we have shown that the MR6 antibody has an inhibitory effect on the in vitro immune responsiveness of T and B lymphocytes a b (Larche et al., 1988a,b) . This raises the intriguing possibility that when administered in vivo the murine monoclonal antibody MR6 might inhibit the immune response to itself, thus avoiding the generation and subsequent problems of a human anti-mouse Ig response in patients receiving immunotherapy (Courtenay-Luck et al., 1987) .
